ProKidney (PROK) Director Brian JG Pereira Sells Shares

What Happened
Brian JG Pereira, a director of ProKidney Corp. (PROK), reported multiple open‑market sales (Code S) totaling 757,164 shares across August 18–20, 2026. The sales generated aggregate proceeds of approximately $1,067,773. Transactions were reported with weighted average prices of $1.37, $1.44 and $1.42 on the respective trade dates; the filing notes the shares were sold in multiple executions at prices within specified ranges.

Key Details

• Transactions (open‑market sales):
  • 2026-08-18: 229,338 shares at a weighted avg $1.37 — $314,468 (footnote: trades ranged $1.345–$1.40)
  • 2026-08-18: 27,826 shares at a weighted avg $1.37 — $38,155 (same range)
  • 2026-08-19: 222,949 shares at a weighted avg $1.44 — $321,203 (footnote: trades ranged $1.38–$1.50)
  • 2026-08-19: 27,051 shares at a weighted avg $1.44 — $38,972 (same range)
  • 2026-08-20: 222,948 shares at a weighted avg $1.42 — $316,564 (footnote: trades ranged $1.38–$1.47)
  • 2026-08-20: 27,052 shares at a weighted avg $1.42 — $38,411 (same range)
• Total sold: 757,164 shares for ~ $1,067,773 in proceeds.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes: Prices reported are weighted averages; the filing discloses transaction price ranges (F1: $1.345–$1.40; F2: $1.38–$1.50; F3: $1.38–$1.47) and states the reporting person will provide per‑trade price details on request.
• Filing date: Aug 20, 2026 (filing appears timely based on the reported trade dates).

Context
These were open‑market sales by a company director. Sales do not necessarily signal insider pessimism (they can be routine or for personal liquidity), and no purchase or derivative exercise was reported in this filing. If you need the post‑transaction beneficial ownership or per‑trade price details, those can be requested from the company or SEC staff as noted in the footnotes.